Sees FY25 adjusted EBITDA margin up 25 basis points. Says mortgage was stronger than expected. Says despite strong Q1 and Q2 guidance, ...

Cherry SE: Cherry SE recognizes asset impairment for 2024; updates adjusted EBITDA margin for fiscal year 2024 11-Apr-2025 / 18:23 CET/CEST Disclosure of an inside information acc. to Article 17 ...

CEO Anderson expressed confidence in achieving double-digit adjusted EBITDA growth in 2025. CFO Sabrina Simmons outlined three financial priorities: gross margin expansion, SG&A leverage ...

Adjusted EBITDA, adjusted EBITDA margin, adjusted net income, adjusted basic and diluted earnings per share, and free cash flow are non-GAAP financial measures. See "Non-GAAP Financial Measures ...

unadjusted EBITDA margin at 26.2% (Adjusted) EBITDA of EUR 315.6 million produces adjusted EBITDA margin of 26.7%; adjustments decrease considerably to EUR 6.7 million compared to 2023 Dermapharm ...

Adjusted EBITDA Margin: 24% in Q3, up from 21% last year. Net Sales: $305 million, a 3.9% decrease from $317 million in the prior year quarter. Revenue Growth (Excluding SES): Over 8% in Q3.

As a result of the MBO and further cost optimisations in the group, the adjusted EBITDA margin is on track to expand to 30% in 2025. Following this MBO, Physitrack is now more streamlined and ...

EBITDA margin widened to 2.6 % in the fourth quarter from 2.2 % in the preceding three months. Standalone operating revenue rose 9.5 % quarter-on-quarter to Rs. 522 crore. Operating expenses rose ...

EBITDA and EBITDA margin in the second quarter of 2025 (as of March 31, 2025). The company expects Q2 2025 revenues of EUR 252m, corresponding to a year-over-year growth of 10% at constant currencies.